Gilde Healthcare
en nl de
  • Portefeuille
  • Team
  • Nieuws
  • Over ons
  • Contact

Nieuws 2016

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

Moximed: First Patient Treated in US Study of Atlas® System for Unicompartmental Knee Osteoarthritis

29 november 2016 – Shock Absorber for the Knee Targets Patients Who Are Seeking Alternatives to Joint Replacement HAYWARD, Calif. – Moximed®, Inc. announced today that the first patient has been treated in an FDA-approved IDE study for its latest generation unicompartmental unloading implant, the Atlas…

Gerelateerd aan: Moximed

Stadsvilla Enschede krijgt nieuwe woonzorgbestemming

14 november 2016 – Stepping Stones Home & Care opent 11e zorgvilla voor zorgbehoevende ouderen De prachtige stadsvilla aan de Hogelandsingel 21 in Enschede krijgt een nieuwe bestemming. Stepping Stones Home & Care realiseert hier als nieuwe huurder een kleinschalige woonzorgvoorziening met 24 appartementen…

Gerelateerd aan: Stepping Stones

ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients

27 oktober 2016 – Topline data to be presented today at NACFC LEIDEN, the Netherlands (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that clinical study PQ-010-002, a proof-of-concept study of nasal potential difference (NPD), demonstrated that QR-010 restored CFTR function…

Gerelateerd aan: ProQR Therapeutics

Sanifit announces initiation of first clinical trial of SNF472 in patients with calciphylaxis

20 oktober 2016 – San Diego, USA and Palma, Spain - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced successful initiation of the first clinical trial of its lead candidate, SNF472, for the treatment of the orphan…

Gerelateerd aan: Sanifit

STAT-Diagnostica Attracts Siemens Venture Capital as a New Investor

5 oktober 2016 – Funding will be used to support go-to-market activities in Europe BARCELONA – Medical diagnostics company STAT-Diagnostica has closed an extension of its Series C financing with Siemens Venture Capital. The additional proceeds will be used to support the 2017 European launch of its…

Gerelateerd aan: STAT-Dx QIAGEN

Acacia Pharma announces positive Phase 3 results in post-operative nausea and vomiting

12 augustus 2016 – Acacia Pharma announces positive results from a pivotal Phase 3 trial of BAREMSIS™ for the treatment of post-operative nausea and vomiting BAREMSIS now shown to treat PONV, as well as prevent it Cambridge, UK – Acacia Pharma Group plc ("Acacia Pharma"), the supportive care company…

Gerelateerd aan: Acacia Pharma

Gilde Healthcare participates in $93 million equity round for cardiovascular company CVRx

11 augustus 2016 – Equity Offering to Support Heart Failure Trial and European Commercial Expansion Minneapolis – CVRx, Inc., a private medical device company, has announced an equity financing totaling $93 million. Gilde Healthcare participated in the financing alongside existing investors, Johnson…

Gerelateerd aan: CVRx

Gilde Healthcare leads USD 20 million financing round of Belgian sleep therapy company Nyxoah

7 juli 2016 – Board will be strengthened with industry experts and Enrique Vega appointed as new CEO Mont-Saint-Guibert, Belgium – Nyxoah S.A., a medical device company focused on developing a neurostimulation based, disruptive therapy for patients suffering from Obstructive Sleep Apnea (OSA),…

Gerelateerd aan: Nyxoah

Gilde Healthcare participates in EUR 12.5 million round of Dutch sleep apnea scale-up NightBalance

5 juli 2016 – NightBalance raises EUR 12.5 million to support the commercial roll-out of the Sleep Position Trainer in Europe and the U.S. Supervisory Board and Management team strengthened with industry experts Delft, the Netherlands – NightBalance BV, a leading innovator of obstructive sleep…

Gerelateerd aan: NightBalance

Gilde Healthcare closes oversubscribed €250 million ($285 million) later stage and growth capital fund

14 juni 2016 – New fund targets innovative scale-up opportunities in medtech, digital health and therapeutics Utrecht, The Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the European specialist investment firm, today announces the final close of Gilde Healthcare IV, a €250 million…

Sanifit appoints Preston S. Klassen MD, MHS as Chief Medical Officer and announces new US Subsidiary

8 juni 2016 – Former Head of R&D at Orexigen Therapeutics and Therapeutic Area Head for Nephrology at Amgen appointed as CMO CMO appointment and launch of US subsidiary are significant steps in establishing a US presence Palma de Mallorca, Spain - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical…

Gerelateerd aan: Sanifit

Moximed’s Atlas™ Knee System Improves Pain Scores and Returns Function to Pre-Arthroplasty Patients with Medial Knee Osteoarthritis

10 mei 2016 – Results from Multi-center, Prospective Study with Unicompartmental Joint Unloading Device for the Knee Presented at ESSKA / Moximed Commercializing Atlas System in Europe

Gerelateerd aan: Moximed

Agendia's MammaPrint® First and Only Genomic Test to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients

19 april 2016 – Agendia, Inc. announced that using the company's MammaPrint® assay, patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biological criteria can avoid chemotherapy.

Gerelateerd aan: Agendia

Symphogen Initiates Anti-MET Clinical Program

12 april 2016 – And Presents Pre-Clinical Anti-MET Data at Annual AACR Meeting April 18th in New Orleans

Gerelateerd aan: Symphogen

Gilde Healthcare leads EUR 25 million financing round of Medical Diagnostics company STAT-Diagnostica

11 april 2016 – Medical diagnostics company STAT-Diagnostica has closed a Series C financing round totaling EUR 25 million. The proceeds will be used to prepare for the 2017 European launch of its DiagCORE Near Patient Testing system.

Gerelateerd aan: STAT-Dx QIAGEN

Acacia Pharma initiates second pivotal Phase 3 treatment study with BAREMSIS™ (APD421) in post-operative nausea & vomiting (PONV)

21 maart 2016 – Acacia Pharma Group announces the initiation of its second pivotal Phase 3 treatment study, investigating BAREMSIS™ in surgical patients who develop post-operative nausea & vomiting, despite having received antiemetic prophylaxis before surgery.

Gerelateerd aan: Acacia Pharma

NIZO food research samen met Gilde Healthcare verder voor groei

7 maart 2016 – Ede - NIZO food research, een internationale contract research organisatie (CRO) voor bedrijven actief in voeding en gezondheidsmarkten, kondigt vandaag aan dat Gilde Healthcare is toegetreden als aandeelhouder om lange termijn groei verder te faciliteren. Jasper van Gorp, Managing…

Gerelateerd aan: NIZO

Inova Labs acquired by ResMed

12 januari 2016 – SAN DIEGO, Calif. – ResMed (NYSE:RMD), a leading innovator in sleep-disordered breathing and respiratory care, today announced it has entered into a definitive agreement to acquire Inova Labs Inc., a privately-held medical device company specializing in the development and commercialization…

Gerelateerd aan: Inova Labs

Acacia Pharma announces positive results from second pivotal Phase 3 study of BAREMSIS™ (APD421) in prevention of post-operative nausea & vomiting

6 januari 2016 – Cambridge, UK – Acacia Pharma Group plc, the supportive care company developing products for US and international markets, announces positive results from a Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) in combination with standard antiemetics for…

Gerelateerd aan: Acacia Pharma

Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology

4 januari 2016 – Partnership aims to advance development of novel immune checkpoint therapies as Baxalta expands oncology leadership in orphan diseases Symphogen to receive $175 million (€160 million) upfront, in addition to potential future milestone payments and royalties BANNOCKBURN, Ill. and…

Gerelateerd aan: Symphogen

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare is een gespecialiseerde Europese investeringsmaatschappij met €1.4 miljard ($1.5 miljard) onder beheer in twee aparte fondsstrategieën: venture & groeikapitaal en private equity. Gilde Healthcare's venture & groeikapitaalfonds participeert in medische technologie en nieuwe geneesmiddelen. De venture & groeibedrijven zijn gevestigd in Europa en Noord Amerika. Gilde Healthcare’s private equity fonds neemt deel in winstgevende Europese bedrijven met een primaire focus op de middenmarkt in Benelux en Duitstalige landen. Het private equity fonds is gericht op zorgverleners, toeleveranciers en producenten van medische producten en overige dienstverleners actief in de zorgsector.

Investeringsfilosofie

Gilde Healthcare investeert in snelgroeiende, innovatieve bedrijven die betere zorg tegen lagere kosten mogelijk maken.

  • Home
  • Portefeuille
  • Team
  • Nieuws
  • Contact
  • Imprint
  • Privacy Policy